Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid products for medical, dermatological, veterinary, and surface disinfection markets worldwide, operating globally with regulatory approvals and partnerships.

# Company Overview: Sonoma Pharmaceuticals, Inc.

## Business Description
- **Industry:** Global healthcare and medical device manufacturing
- **Specialization:** Developing and producing **stabilized hypochlorous acid (HOCl)** products
- **Applications of Products:** 
  - Wound care
  - Eye care
  - Oral care
  - Dermatological conditions (e.g., eczema, atopic dermatitis, scars, acne)
  - Podiatry
  - Animal health care
  - Non-toxic disinfectants for surfaces

## Product Characteristics
- Clinically proven to reduce itch, pain, scarring, and irritation
- Safe and non-damaging to healthy tissue
- Effectively manages skin abrasions, lacerations, minor irritations, cuts, and intact skin
- Stability advantages over similar market products

## Market Reach & Global Presence
- Operates in **over 55 countries**
- Sells both directly and through partners/distributors
- Focus on international expansion with regulatory approvals (EU MDR, UK MHRA, FDA approvals)
- *Core markets*: US, Europe, Asia, Latin America

## Revenue & Financials
- **Fiscal Year End:** March 31
- **2025 Revenue:** approximately **$14.3 million** (up from $12.7 million in 2024)
  - **By region:**
    - U.S.: $2.6 million (15% decrease from prior year)
    - Europe: $5.5 million (16% increase)
    - Asia: $2.3 million (stable)
    - Latin America: $3 million (72% increase)
    - Rest of the world: $0.9 million
- **Net Loss (2025):** **$3.46 million**
  - Compared to **$4.84 million** in 2024
- **Employees:**
  - **Total employees (June 12, 2025):** 7 full-time in the U.S., 1 in the Netherlands, approximately 160 in Mexico

## Key Product Lines
- **Dermatology:** Prescription and OTC products (e.g., Epicyn, Levicyn, Celacyn, Reliefacyn, Rejuvacyn, Lumacyn)
- **Wound & Acute Care:** 
  - Products like Microcyn (for wounds, burns, infections)
  - Intraoperative pulse lavage solutions
  - Negative Pressure Wound Therapy products
- **Eye Care:** 
  - Prescription: Acuicyn (blepharitis, eyelid/eyelash hygiene)
  - OTC: Ocucyn
- **Oral & Nasal Care:** 
  - Microdacyn60 Oral Care (mouth/throat infections, thrush)
  - Sinudox (nasal irrigation)
- **Podiatry:** 
  - Wound care for diabetic foot ulcers
  - OTC foot care products (Podiacyn)
- **Animal Health Care:** 
  - MicrocynAH (animal wound and skin infection treatment)
  - MicrocynVS (veterinary strength)
- **Surface Disinfectants:** 
  - Nanocyn 
  - Sold worldwide with approvals including EPA (for COVID-19, other pathogens)
  
## Regulatory & Approvals
- **U.S.:** 22 FDA 510(k) clearances for various medical devices
- **Europe:** CE marks, transitioned to Medical Devices Regulation (MDR) for many products
- **UK:** Registered with MHRA
- **Other:** Approvals in Australia, Canada, Middle East, parts of Asia

## Business Strategy & Focus
- Expanding global regulatory reach
- Increasing revenue through new product launches and approvals
- Forming distribution partnerships (e.g., Medline Industries, WellSpring)
- R&D pipeline of new and expanded products
- Differentiated by stability and safety profile of HOCl-based solutions

---

**Summary:**
Sonoma Pharmaceuticals specializes in creating safe, stable HOCl-based products for medical, dermatological, veterinary, and surface disinfection markets worldwide. It operates globally through direct sales and partnerships, with a broad regional presence and regulatory approval framework. The company reported approximately $14.3 million in revenue for FY2025, employs around 168 people across its operations, and incurred a net loss of $3.46 million in the same period.

Sonoma Pharmaceuticals, Inc. is a global healthcare leader specializing in the development of stabilized hypochlorous acid products for various medical applications.

# Company Overview: Sonoma Pharmaceuticals, Inc.

## Business Description
Sonoma Pharmaceuticals, Inc. is a global healthcare leader focused on developing and producing stabilized hypochlorous acid (HOCl) products for a variety of applications, including:

- **Wound Care**
- **Eye Care**
- **Oral Care**
- **Dermatological Conditions**
- **Podiatry**
- **Animal Health Care**
- **Non-toxic Disinfectants**

The company's products are clinically proven to safely reduce itch, pain, scarring, and irritation without damaging healthy tissue. In-vitro and clinical studies support the effectiveness of HOCl in managing skin abrasions, lacerations, minor irritations, and intact skin.

## Market Presence
- **Geographic Reach:** Sonoma sells its products in **55 countries** worldwide.
- **Customers:** The company has established relationships with a broad range of customers, including hospitals, medical centers, doctors, pharmacies, distributors, and wholesalers.
- **Key Partnerships:** The company partners with distributors both in the United States and internationally to enhance its market reach.

## Financial Highlights
- **Number of Employees:** As of June 17, 2024, Sonoma employs a total of **10 full-time employees** in the U.S. (9) and the Netherlands (1), along with **162 employees** in Mexico.

### Fiscal Year Overview (2024)
- **Revenue:** Total revenue for the year ended March 31, 2024, was **$12.735 million**, a decrease of approximately **4%** from **$13.272 million** in 2023.
- **Net Loss:** The company reported a net loss of **$4.835 million** for the year, slightly less than the **$5.151 million** loss incurred in the previous year. The accumulated deficit as of March 31, 2024, totaled **$194.349 million**.
- **Gross Profit:** The gross profit increased to **$4.745 million** in 2024, up **6%** from **$4.477 million** in 2023.
- **Research and Development Expenses:** The research and development expenses surged to **$1.871 million** in 2024, compared to **$207,000** in the previous year, reflecting increased product development and regulatory efforts.
- **Cash Position:** As of March 31, 2024, the company had cash and cash equivalents of **$3.128 million**.

## Strategy and Future Outlook
Sonoma Pharmaceuticals aims to capitalize on its unique HOCl technology, expand its product offerings, and penetrate international markets. The company continues to invest in research and development to create innovative products and enhance its regulatory approvals to meet diverse market needs.

## Conclusion
Sonoma Pharmaceuticals positions itself as a significant player in healthcare by offering clinically validated products, expanding its distribution and customer base, and focusing on innovative solutions to address unmet medical needs.

Sonoma Pharmaceuticals, Inc.

10-K / June 17, 2025

10-K / June 17, 2024

10-K / June 17, 2025

Company Overview: Sonoma Pharmaceuticals, Inc.

Business Description

Product Characteristics

Market Reach & Global Presence

Revenue & Financials

Key Product Lines

Regulatory & Approvals

Business Strategy & Focus